The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 10, 2023

Filed:

Jun. 30, 2017
Applicants:

Hoffmann-la Roche Inc., Little Falls, NJ (US);

Ludwig-maximilians-universitat Munchen, Munich, DE;

Inventors:

Christian Klein, Bonstetten, CH;

Claudio Sustmann, Munich, DE;

Gerhard Niederfellner, Oberhausen, DE;

Martina Geiger, Obfelden, CH;

Stefan Endres, Munich, DE;

Sebastian Kobold, Munich, DE;

Assignee:

Other;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 14/71 (2006.01); C12N 5/0783 (2010.01); A61P 35/00 (2006.01); A61K 39/395 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0011 (2013.01); A61K 39/39558 (2013.01); A61P 35/00 (2018.01); C07K 14/71 (2013.01); C07K 16/2863 (2013.01); C07K 16/30 (2013.01); C07K 16/3053 (2013.01); C12N 5/0636 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/545 (2013.01); C07K 2317/14 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/60 (2013.01); C07K 2317/64 (2013.01); C07K 2319/00 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01);
Abstract

The present invention generally relates to T-cells, such as CD8+ T-cells, CD4+ T-cells, CD3+ T-cells, γδ T-cells or natural killer (NK) T-cells, transfected/transduced with a fusion protein which is recruited by the use of trivalent, bispecific antibody molecule which specifically binds to/interacts with the extracellular domain of the fusion protein. More precisely, the present invention relates to a kit comprising the nucleic acid molecules, vectors and/or the fusion proteins of the present invention and the trivalent, bispecific antibody molecules of the present invention. Further aspects of the inventions are expression vectors comprising nucleic acid molecules encoding the fusion proteins as well as the trivalent, bispecific antibody molecules. Further, a process for the production of the trivalent, bispecific antibody molecules of the invention and a medicament/pharmaceutical composition comprising said trivalent, bispecific antibody molecules are described. The invention also provides the use of said trivalent, bispecific antibody molecules in a method for the treatment of particular diseases as well as a pharmaceutical compositions/medicament comprising said trivalent, bispecific antibody molecules, wherein said trivalent, bispecific antibody molecule(s) is (are) to be administered in combination with transduced T-cells comprising the fusion protein of the invention. The invention also provides a method for the treatment of particular diseases.


Find Patent Forward Citations

Loading…